<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2017-09-08" updated="2019-12-02">
  <drugbank-id primary="true">DB13888</drugbank-id>
  <drugbank-id>DB10073</drugbank-id>
  <name>Meningococcal polysaccharide vaccine group Y</name>
  <description>Meningococcal group Y polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup Y. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.</description>
  <cas-number/>
  <unii>CBZ4BH7TJ1</unii>
  <groups>
    <group>approved</group>
    <group>experimental</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Meningococcal polysaccharide antigen group Y</synonym>
    <synonym language="english" coder="">Neisseria meningitidis group Y capsular polysaccharide antigen</synonym>
    <synonym language="english" coder="">Neisseria meningitidis group Y polysaccharide antigen, A</synonym>
  </synonyms>
  <products>
    <product>
      <name>Menhibrix</name>
      <labeller>GlaxoSmithKline Biologicals SA</labeller>
      <ndc-id/>
      <ndc-product-code>58160-809</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-03</started-marketing-on>
      <ended-marketing-on>2013-11-27</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number>BLA125363</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menhibrix</name>
      <labeller>GlaxoSmithKline Biologicals SA</labeller>
      <ndc-id/>
      <ndc-product-code>58160-801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-03</started-marketing-on>
      <ended-marketing-on>2017-09-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number>BLA125363</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menomune - A/c/y/w-135 Combined</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code>49281-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103924</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menomune-A/c/y/w-135</name>
      <labeller>Aventis Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02161184</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-08-13</started-marketing-on>
      <ended-marketing-on>2006-07-17</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menomune-A/c/y/w-135</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959018</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-10-29</started-marketing-on>
      <ended-marketing-on>2017-04-05</ended-marketing-on>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menomune-A/c/y/w-135</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00588490</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-04-05</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menveo</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347393</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution; Solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nimenrix</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02402904</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Menhibrix</name>
      <ingredients>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Menomune - A/c/y/w-135 Combined</name>
      <ingredients>Meningococcal polysaccharide vaccine group A + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group W-135 + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Menhibrix</name>
      <ingredients>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Menomune-A/c/y/w-135</name>
      <ingredients>Meningococcal polysaccharide vaccine group A + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group W-135 + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Menveo</name>
      <ingredients>Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine + Meningococcal polysaccharide vaccine group A + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group W-135 + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Menomune-A/c/y/w-135</name>
      <ingredients>Meningococcal polysaccharide vaccine group A + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group W-135 + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Menomune-A/c/y/w-135</name>
      <ingredients>Meningococcal polysaccharide vaccine group A + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group W-135 + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
    <mixture>
      <name>Nimenrix</name>
      <ingredients>Clostridium tetani toxoid antigen (formaldehyde inactivated) + Meningococcal polysaccharide vaccine group A + Meningococcal polysaccharide vaccine group C + Meningococcal polysaccharide vaccine group W-135 + Meningococcal polysaccharide vaccine group Y</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Actively Acquired Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Inactivated Meningococcal Vaccine</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution; solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13888.pdf?1505428589</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7668</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911457</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>